April 12th 2024
LYT-200 is currently being investigated for those with solid tumors and hematologic malignancies.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Nivolumab Approved for Squamous Cell Carcinoma of the Head and Neck
November 14th 2016The US Food and Drug Administration (FDA) in record time has approved nivolumab (Opdivo) for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after a platinum-based therapy.